King Stuki re: BIPH.ob. I've been holding all my shares from $0.40 and haven't let go of any yet. I believe BIPH will prove to be good stock to hold for the long-term gains column. BIPH is currently in a quiet period awaiting SEC approval of their registration statement....so news items have been thin lately. They've filed 3 SB-2s since the filing of their RegDex to clear up issues with the SEC. Since they've been in the quiet period they've been allowed six more patents from the USPTO, two of which have been announced....I would expect the others to be announced once they are out of the quiet period?
Furthermore, the latest SB-2 included these additional details about their partenership with BSX:
On September 25, 2003, we entered into a development agreement with Boston Scientific Corp., a biomedical device company. The purpose of this agreement is to establish a framework to explore the use of our technology to make one of Boston Scientific's products MRI safe and image compatible. The agreement contemplates three phases, to be completed over a period of seven months. The first phase has been completed and we have recorded $75,000 of revenues that we received for our services provided in the first phase. Boston Scientific has the right to elect to proceed with second and third phases. The aggregate development payments relating to the second and third phases if Boston Scientific elects to proceed with them is $225,000. We are discussing with Boston Scientific potential changes to the scope of the second and third phases based on the results from the first phase. We are also discussing initiatives with other divisions of Boston Scientific which are outside the scope of the agreement. If Boston Scientific elects to proceed with additional phases under the agreement and such phases are completed and successful, or if one or more of our other initiatives being discussed with Boston Scientific proceeds, it may lead to a license for one or more of our technologies in the context of one or more product lines. We can make no assurances that we will be able to enter into any such license agreement. As part of this agreement, we have offered Boston Scientific a period of first right of negotiation for the application our technology to their product, extending through May 15, 2004. Because of the limited payments potentially due to us under the agreement with Boston Scientific, the amount of our other resources and the commitment of SBI under the stock purchase agreement, we are not substantially dependent on the Boston Scientific agreement.
So this would lead me to believe we should know more in a month or less about the BSX relationship.....and if Boston Scientifics taxus stent gets mentioned in a joint PR from BIPH ansd BSX I can't even imagine how the market would bid up BIPH.
Nothing is certain; but if you read the SB-2 BIPH has several irons in the fire....and I believe patience will be rewarded there.
Good luck!
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
